Zacks small cap research.

CXW intends to redeem the $153.9 million outstanding of its 4.625% senior notes that mature in 2023 in full on February 1, 2023, using a combination of cash on hand and existing capacity under its revolving credit facility. CXW had $185.3 million of cash at the end of 3Q22 and its $250.0 million revolver was undrawn.Jun 14, 2023 · Raises Gross Proceeds of $55 Million to Advance Lead Compound to Clinical Trials. On My 17, 2023, Satellos Biosciences Inc. (OTC:MSCLF) announced it closed an equity offering in which it raised gross proceeds of $55 million from the issuance of 110 million equity securities at $0.50 per common share or pre-funded warrant (70,297,220 common ... © Zacks Small Cap Research - All rights reserved Powered By Q4 Inc. 5.111.2.6 (opens in new window) 5.111.2.6 (opens in new window) 16 Feb 2022 ... With Sharesight, investors can get Zacks Investment Research news directly in their portfolio for US stocks. ... Small Caps and ausbiz. Sharesight ...

By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Third Quarter Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported 3Q:23 results on November 13, 2023 via its filing of Form 10-Q with the SEC. Since the filing of the second quarter 10-Q in mid-August, the company has finished compiling and submitting its investigational new drug (IND)Apr 7, 2022 · YY. 40.15. +4.02%. A complete archive of Small-cap articles from Zacks Investment Research. Our Research, Your Success. ZACKS SMALL/MID CAP ETF. The Zacks Small/Mid Cap ETF seeks to generate consistent and sustainable returns while minimizing the risk of capital …

Reviva’s Phase III trial designated RECOVER is now underway, a four-week efficacy study followed by a one-year safety extension. The trial will target enrollment of 400 subjects, which as of July 2022 was 20% achieved and continuing to progress slightly ahead of schedule. Based on the construction of the study, which could be extended due to ...

Forgot your password? Email us at [email protected] for assistance ...Zacks Small-Cap Research Sponsored – Impartial - Comprehensive Lisa Thompson 312-265-9517 [email protected] Sponsored – Impartial - Comprehensive …Zacks Small Cap Research. TENX: Prioritizing Levosimendan. Read full article. Zacks Small Cap Research. May 22, 2023 at 6:44 AM ...When it comes to maintaining and enhancing the appearance of your vehicle, even the smallest details matter. One such detail that often goes overlooked is the wheel center caps. These small, circular covers not only add a touch of style to ...

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

Nov 13, 2023 · By Brad Sorensen, CFA NASDAQ:ONVO READ THE FULL ONVO RESEARCH REPORT Organovo (NASDAQ:ONVO) reported its fiscal 2Q earnings and results were roughly inline with our expectations and illustrate to us that the company continues to progress toward bringing important products to market. Specifically, the company reported: • Earnings of -$0.46 per share, in line with estimates as expenses remained

By Thomas Kerr, CFA. NASDAQ:GRIL. READ THE FULL GRIL RESEARCH REPORT. Muscle Maker Inc. (NASDAQ:GRIL), has evolved into a diversified, global food company with two distinct business units: 1) Sadot LLC – an international agricultural commodity supply-chain organization and 2) MMI Restaurant Group – an operator and franchisor of 50+ healthier-for-you fast casual concepts plus a subscription ...SCR Premium. Receive Initiation Reports PROMPTLY as they are sent out to the marketplace. Access the FULL REPORT CATALOG on any company we cover. Receive the DAILY ALERT EMAIL, containing all of the day's updates, around 5 p.m. EST. Access to REAL-TIME EMAIL ALERTS for any companies covered by Zacks SCR analysts.. …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.Dec 1, 2022 · By David Bautz, PhD. NASDAQ:QLGN. READ THE FULL QLGN RESEARCH REPORT. Business Update . Preclinical Data on QN-302 Presented at AACR Conference on Pancreatic Cancer . In September 2022, Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced the presentation of two posters on QN-302 at the AACR 8 th Special Conference on Pancreatic Cancer.

When it comes to wheels, one small but important component that often goes unnoticed is the wheel center cap. These caps not only add a touch of style to your vehicle’s wheels but also serve several practical functions.Thermon Holding has a market cap of $669.2 million and a VGM Score of A. The Zacks Consensus Estimate for its current-year and 2023 earnings has improved 19.4% and 12.6% over the past 30 days to ...Zacks Small Cap Research. TENX: Notice of Allowance Increases Confidence. Read full article. Zacks Small Cap Research. June 23, 2023 at 3:24 AM ...Aug 24, 2023 · By Lisa Thompson OTC:NEXCF CSE:TGGL READ THE FULL NEXCF RESEARCH REPORT Nextech (OTC:NEXCF) reported Q2 revenues of $1.4 million, up $100,000 sequentially from Q1 and 153% from Q2 2022. The company had preannounced this number on August 1st. Investors are still awaiting news that Nextech’s 3D modeling services will be available to merchants in Amazon’s Seller Central which is expected to boost Zacks Rank N/A FY21 Results; IO Revenues Analysis Zacks Small-Cap Research John D. Vandermosten, CFA Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 January 11, 2022 312-265-9588 / [email protected] Revenue Q1 Q2 Q3 Q4 Year (Dec) (Mar) (Jun) (Sep) (Sep)Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted results from its Ongoing Research of Cytisinicline for Addiction, Vaping (ORCA-V1) trial and hosted a conference call for investors on April 20, 2023. The Phase II ORCA-V1 trial was conducted to measure the safety and effectiveness of 3 mg of cytisinicline dosed three times daily for 12 weeks ...Novonix Cathode Materials is also expected to play a key role in the growing demand for batteries. Last month NVX launched a new pilot production facility for cathode materials in a new 35,000-square-foot facility. The facility enables Novonix to demonstrate the feasibility of large-scale production.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …By Brad Sorensen, CFA OTC:PBSV READ THE FULL PBSV RESEARCH REPORT Pharma-Bio Serv (OTC:PBSV) announced 2Q 2023 results. The headline showed that earnings per share of $0.02 were inline with our estimates, driven by the continued impressive improvement in gross margin on sales revenue by another 5% in the quarter …

Nov 22, 2023 · Research and development expenses in the 3rd quarter of 2023 were $469,000 which was similar to R&D expenses in the 3rd quarter of 2022 of $468,000. R&D expenses include the use of third-party contractors for further R&D activities, the performance of usability studies for the PressureSafe device, and non-cash expenses relating to stock-based ... How many stars would you give Zacks Investment Research? Join the 86 people who've already contributed. Your experience matters.Apr 26, 2023 · By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update First Patient Dosed in Phase 1b/2 Trial for Exebacase in Chronic Knee Prosthetic Joint Infections On April 26, 2023, ContraFect Corp. (NASDAQ:CFRX) announced the first patient has been dosed in the Phase 1b/2 clinical trial of exebacase in the setting of a minimally-invasive arthroscopic debridement, antibiotics, By John Vandermosten, CFA. NASDAQ:RVPH. READ THE FULL RVPH RESEARCH REPORT. 2Q:23 Financial and Operational Results. On August 15, 2023, Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) reported 2Q:23 financial and operational results and filed its Form 10-Q with the SEC. Since our previous update in …Zacks Equity Research November 23, 2023. CVX Quick Quote CVX ... Overall, they are usually a stable option, with less risk and more sure-fire cash flows than …1. Source: Created by Zacks Small Cap Research Analysts. By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT BALANCE Interim Results On June 2, 2021, Protalix and development partner, Chiesi Global Rare Diseases, provided an update regarding clinical development of Protalix’ candidate pegunigalsidase alfa (PRX …1. Source: Created by Zacks Small Cap Research Analysts. By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT BALANCE Interim Results On June 2, 2021, Protalix and development partner, Chiesi Global Rare Diseases, provided an update regarding clinical development of Protalix’ candidate pegunigalsidase alfa (PRX …

By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT While the clinical trial for LP-300 is ongoing in never-smoker, non-small cell lung cancer patients, Lantern Pharma, Inc. (NASDAQ:LTRN) has been busy advancing some of its earlier stage assets including LP-184 and LP-284. These small molecule acylfulvenes are chemically related as LP-284 is the positive enantiomer of LP-184.

On September 18, 2023, ContraFect Corp. (NASDAQ:CFRX) announced that it had submitted an Investigational New Drug (IND) application to the U.S. FDA on September 15, 2023 for CF-370 for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). The FDA has 30 days to …

Update on Phase 1 Trial of EPI-7386. ESSA Pharma Inc. (NASDAQ:EPIX) is currently conducting a Phase 1 clinical trial of EPI-7386 in patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed on two or more systemic therapies, including at least one second generation anti-androgen therapy ( NCT04421222 ).LEXX: GLP-1s’ Sweet Opportunity. Lexaria Bioscience Corporation (NASDAQ:LEXX) reports fiscal full year 2023 results along with program updates, new deals and a small capital raise since the third quarter report in August. The company announced that the investigational new drug (IND) application would be delayed on account of a supplier. Jan 5, 2023 · By Thomas Kerr, CFA NASDAQ:UXIN READ THE FULL UXIN RESEARCH REPORT On December 30th, Uxin (NASDAQ:UXIN) reported fiscal 2nd quarter operating and financial results for the three-month period ending September 30, 2022. Total revenues increased to $87 million which was a 1.2% increase from the fiscal 1st quarter and a 78.9% increase from the prior year period. Unit volume was 6,050 vehicles in the Similar to other regions, penetration into the near 22,000 low risk SCCHN cases is expected to start at 3% and rise to 30% by year six then market share stabilization and declines in 2033 and 2034. The final geography that we include in our DCF model is the UK. According to Cancer Research UK, there are about 12,400 head and neck cancers.Sep 29, 2023 · By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT While the clinical trial for LP-300 is ongoing in never-smoker, non-small cell lung cancer patients, Lantern Pharma, Inc. (NASDAQ:LTRN) has been busy advancing some of its earlier stage assets including LP-184 and LP-284. These small molecule acylfulvenes are chemically related as LP-284 is the positive enantiomer of LP-184. Mar 31, 2023 · In 4Q22, Novonix Anode Materials was selected to enter negotiations to receive US$150 million in grant funding from the Department of Energy (DOE) to expand its domestic synthetic graphite anode materials production, which we view as a positive. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you ... By Thomas Kerr, CFA NASDAQ:UXIN READ THE FULL UXIN RESEARCH REPORT On December 30th, Uxin (NASDAQ:UXIN) reported fiscal 2nd quarter operating and financial results for the three-month period ending September 30, 2022. Total revenues increased to $87 million which was a 1.2% increase from the fiscal 1st quarter and a 78.9% increase from the prior year period. Unit volume was 6,050 vehicles in theIn 4Q22, Novonix Anode Materials was selected to enter negotiations to receive US$150 million in grant funding from the Department of Energy (DOE) to expand its domestic synthetic graphite anode materials production, which we view as a positive. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Highlights for 2022 and to-date include: TLANDO approved – March 2022. LPCN 1144 end of Phase II meeting with FDA – July 2022. LPCN 2101 IND cleared – July 2022. LPCN 1154 (post-partum depression) pathway to approval clarified – September 2022. Strategic realignment towards CNS disorders – September 2022.

Thermon Holding has a market cap of $669.2 million and a VGM Score of A. The Zacks Consensus Estimate for its current-year and 2023 earnings has improved 19.4% and 12.6% over the past 30 days to ...Research and development expenses in the 3rd quarter of 2023 were $469,000 which was similar to R&D expenses in the 3rd quarter of 2022 of $468,000. R&D expenses include the use of third-party contractors for further R&D activities, the performance of usability studies for the PressureSafe device, and non-cash expenses relating to stock-based ...Research and development expenses in the 3rd quarter of 2023 were $469,000 which was similar to R&D expenses in the 3rd quarter of 2022 of $468,000. R&D expenses include the use of third-party contractors for further R&D activities, the performance of usability studies for the PressureSafe device, and non-cash expenses relating to stock-based ...Instagram:https://instagram. electric car battery stockschase home loan refinance ratesblink stocksbuy stock in apple Image: Bigstock 5 Top-Ranked Small-Cap Stocks to Boost Your Portfolio in 2021 (revised) Nalak Das December 14, 2020 TITN HZO STRT Better trading starts … assurant liability insurancebaron growth fund SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting … hertz stokc When it comes to maintaining the aesthetics and functionality of your wheels, OEM wheel center caps play a crucial role. These small but significant accessories not only add a touch of style to your vehicle’s appearance but also provide ess...'Who needs breadth when we have Nvidia's beat?': We've been here before, and I can tell you it lasts longer than it should. Let's look at charts and indicators, past and present....NVDA We're in that part of the cycle wh...SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …